morn report result line revenu beat ten cent
ep notabl organ growth quarter y/i much stronger
expect lift stock today re-affirmed organ growth y/
view room upsid gross margin bit light
guidanc trim believ mix headwind transitori
confid meaning expans materi go forward believ busi
continu deliv new product flow percuv repla like
lift number like set rest year believ sentiment
improv markedli name given strong organ growth trend reiter
ow rate recommend investor buy stock
morn report sale line street
estim organ growth notabl higher expect fx
headwind contribut growth adj gross margin quarter
bit light lower model mostli due neg product mix
move bottom line ep beat street ten cent mostli due
guidanc report revenu guidanc trim due currenc
y/i previous compani re-affirmed organ
cc growth year notabl margin guidanc come year adjust
gm guidanc trim midpoint op margin
well move year bottom-lin manag rais
rang midpoint vs previou guidanc updat
rang consensu estim lower margin guidanc
ep lift driven lower tax rate view organ cc growth year
midpoint conserv given out-performance quarter
fact face easiest comp year number move part
ep fx tax think expect prudent set also
point call sever key takeaway call earlier today first
strong perform neotract print y/i
contribut includ organ second gross margin
number bit light quarter mani move part transitori
natur mostli mix front think higher margin profil neotract
vsi provid enough oper leverag off-set dynam could
upsid drop bottom line margin expans core thesi
number driver exist go forward form new product accret
restructur organ continu follow page
price close novemb
ep estim
debt total capit
failur realiz margin expans product recal competit
global diversifi medic technolog product provid
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
lastli term next year manag refrain comment issu
guidanc posit bia larg address market captur new product
percuv repla bring revenu number higher investor feel
comfort growth acceler along product provid margin
stock share close higher today believ sentiment
improv markedli name given strong organ growth trend go forward
believ busi continu deliv new product flow percuv
repla like lift number see reason organ growth slow
near term like set rest year recommend investor buy stock
maintain ow rate rais pt base trim target
multipl ep estim multipl pull back across
med tech comp group
page
page
good expens net incom analysi gross analysi vascular north north north north north inc
thousand except per share data
good sold
good sold
percent sale
good sold
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
